Heat Biologics Shares Continue Higher (Up 22%) on Heavy Volume Fri. Following 27% Run-Up on Wed. as $1.50 Resistance Level Breached; BZ NOTE: Co. Announced Last Thursday It will Be Reporting Phase Ib Results for HS-110 In Combo with Bristol's Opdivo Dec. 